Published in Curr Opin Virol on May 04, 2012
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis (2014) 1.80
Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis (2014) 1.72
Development of RNA aptamers targeting Ebola virus VP35. Biochemistry (2013) 0.93
Efficient extraction of proteins from formalin-fixed paraffin-embedded tissues requires higher concentration of tris(hydroxymethyl)aminomethane. Clin Proteomics (2014) 0.89
Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS One (2014) 0.87
A new approach for monitoring ebolavirus in wild great apes. PLoS Negl Trop Dis (2014) 0.86
Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine. Mol Pharm (2013) 0.84
Novel vaccine strategies against emerging viruses. Curr Opin Virol (2013) 0.81
Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection. PLoS One (2015) 0.79
Filoviruses: One of These Things is (not) Like the Other. Viruses (2015) 0.78
Ebola: facing a new transboundary animal disease? Dev Biol (Basel) (2013) 0.77
Fruit bats as reservoirs of Ebola virus. Nature (2005) 11.05
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
Ebola haemorrhagic fever. Lancet (2011) 8.28
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85
Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science (2004) 5.49
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Catastrophic ape decline in western equatorial Africa. Nature (2003) 4.51
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 4.50
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Ebola outbreak killed 5000 gorillas. Science (2006) 3.60
Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis (1999) 3.47
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A (2012) 3.35
Immunization for Ebola virus infection. Nat Med (1998) 3.27
Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol (2004) 3.04
Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis (2009) 2.82
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 2.69
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature (1992) 2.67
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 2.61
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep (2010) 2.31
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis (2010) 2.24
Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med (1996) 2.23
Wave-like spread of Ebola Zaire. PLoS Biol (2005) 2.23
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants. Proc Natl Acad Sci U S A (2007) 2.07
Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06
DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology (1998) 2.02
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Heterologous prime-boost vaccination. Curr Opin Immunol (2009) 1.84
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med (1997) 1.61
Consequences of non-intervention for infectious disease in African great apes. PLoS One (2011) 1.33
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol (2010) 1.29
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol (2011) 1.28
Gorilla susceptibility to Ebola virus: the cost of sociality. Curr Biol (2006) 1.24
Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine (2010) 1.20
Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet (1980) 1.14
Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis (2011) 1.14
Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis (2011) 1.03
Recent advances in Ebolavirus vaccine development. Hum Vaccin (2010) 1.01
Counting primates for conservation: primate surveys in Uganda. Primates (2005) 1.00
Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol (2011) 0.96
Vaccinating the vampire bat Desmodus rotundus against rabies. Virus Res (2008) 0.88
Field anesthesia of free-living mountain gorillas (Gorilla gorilla beringei) from the Virunga Volcano region, Central Africa. J Zoo Wildl Med (2000) 0.79
Indirect oral immunization of captive vampires, Desmodus rotundus. Virus Res (2005) 0.79
Photopolymerized hydrogel carriers for live vaccine ballistic delivery. Vaccine (2005) 0.79
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (2005) 7.07
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med (2006) 3.38
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Generic detection of coronaviruses and differentiation at the prototype strain level by reverse transcription-PCR and nonfluorescent low-density microarray. J Clin Microbiol (2007) 1.89
Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. N Engl J Med (2015) 1.51
Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol (2007) 1.45
Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis (2007) 1.44
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol (2011) 1.28
Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol (2011) 1.28
Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol (2010) 1.22
Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J Virol Methods (2006) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Use of protective gear and the occurrence of occupational Marburg hemorrhagic fever in health workers from Watsa health zone, Democratic Republic of the Congo. J Infect Dis (2007) 1.11
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology (2010) 1.09
Baseline assessment of collaborative tuberculosis/HIV activities in Kinshasa, the Democratic Republic of Congo. Trop Doct (2008) 1.01
Serosurvey on household contacts of Marburg hemorrhagic fever patients. Emerg Infect Dis (2006) 0.89
Pygmy populations seronegative for Marburg virus. Emerg Infect Dis (2005) 0.86
Lessons from the outbreak of Marburg virus. N Engl J Med (2005) 0.75
Improving Posthospital Discharge Telephone Reach Rates Through Prehospital Discharge Face-to-Face Meetings. Prof Case Manag (2017) 0.75